Eli Lilly reported third-quarter earnings that significantly beat analyst estimates, fueled by strong sales of its metabolic drugs Mounjaro and Zepbound. These brands generated $16.1 billion in combined revenue during Q3, contributing to a 39% year-over-year growth in total revenue. Consequently, the company raised its 2026 revenue outlook to a range of $91 billion to $92 billion.
The company raised its 2026 revenue forecast to $91–92 billion, but lowered its adjusted earnings-per-share range due to deal-related research and development charges.
Read the full storyThe company raised its annual revenue forecast to $91–92 billion, while lowering its adjusted EPS outlook due to acquired in-process R&D and acquisition-related charges.